DnB Asset Management
AUPH icon

DnB Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

DnB Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-145,846
Closed -$1.47M – 648
2022
Q2 		$1.47M Sell
145,846
-97,587
-40% -$1.09M 0.01% 555
2022
Q1 		$3.01M Buy
243,433
+9,539
+4% +$147K 0.02% 480
2021
Q4 		$5.35M Sell
233,894
-204,886
-47% -$4.85M 0.03% 361
2021
Q3 		$9.71M Sell
438,780
-185,220
-30% -$2.94M 0.06% 234
2021
Q2 		$8.09M Buy
624,000
+209,069
+50% +$2.66M 0.05% 253
2021
Q1 		$5.39M Buy
414,931
+315,378
+317% +$4.58M 0.04% 304
2020
Q4 		$1.38M Buy
+99,553
New +$1.45M 0.01% 529

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's AUPH Position: Q3 2022 in Review

DnB Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 145,846 shares — an estimated $1.47M sold.

DnB Asset Management first reported a position in AUPH in Q4 2020 and held it in 7 quarters. The position peaked at $9.71M in Q3 2021. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • DnB Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • DnB Asset Management sold 145,846 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $1.47M.
  • DnB Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • DnB Asset Management's Aurinia Pharmaceuticals position peaked at $9.71M in Q3 2021.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on DnB Asset Management's 13F filing for Q3 2022, filed 11 Oct 2022.